4D Molecular Therapeutics Inc

General ticker "FDMT" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $389.3M

4D Molecular Therapeutics Inc does not follow the US Stock Market performance with the rate: -30.2%.

Estimated limits based on current volatility of 5.2%: low 5.64$, high 6.25$

Factors to consider:

  • US accounted for 1.1% of revenue in the fiscal year ended 2022-12-31
  • Current price 39.7% below estimated low
  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [9.75$, 21.72$]
  • 2024-12-30 to 2025-12-30 estimated range: [7.15$, 16.82$]

Financial Metrics affecting the FDMT estimates:

  • Negative: Non-GAAP EPS, $ of -2.66 <= 0.10
  • Negative: Operating profit margin, % of -84.49 <= 1.03
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -10.88 <= 2.35

Similar symbols

Short-term FDMT quotes

Long-term FDMT plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $18.04MM $3.13MM $20.72MM
Operating Expenses $89.37MM $113.16MM $133.59MM
Operating Income $-71.33MM $-110.03MM $-112.87MM
Non-Operating Income $0.02MM $2.54MM $12.03MM
R&D Expense $61.36MM $80.25MM $97.10MM
Income(Loss) $-71.32MM $-107.49MM $-100.84MM
Profit(Loss) $-71.32MM $-107.49MM $-100.84MM
Stockholders Equity $319.11MM $231.34MM $307.83MM
Inventory $8.50MM $5.79MM $0.00MM
Assets $353.49MM $261.85MM $339.89MM
Operating Cash Flow $-69.13MM $-86.69MM $-75.79MM
Capital expenditure $9.11MM $11.54MM $2.77MM
Investing Cash Flow $-172.68MM $-17.05MM $115.72MM
Financing Cash Flow $118.09MM $3.08MM $156.83MM
Earnings Per Share* $-2.46 $-3.12 $-2.58

* EPS are Split Adjusted, recent splits may be reflected with a delay.